arrow
G

Georg Widhalm

medical university vienna
H指数:50
被引数:9,982

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Optical microscopy predictions of focal recurrence in glioblastoma

光学显微镜预测胶质母细胞瘤的局部复发

2026-09-250
OA
Classifying adult-type diffuse glioma using 7T magnetic resonance spectroscopic imaging

利用7T磁共振波谱成像对成人型弥漫性胶质瘤进行分类

2026-09-210
OAAI
Immune remodelling and molecular profiling of progressive brain metastases following cranial radiotherapy

颅脑放射治疗后进展性脑转移瘤的免疫重塑与分子特征分析

2026-08-010
PRE
Clinical potential of [18F]FET PET in patients with circumscribed astrocytic glioma

[18F]FET PET在局限性星形细胞胶质瘤患者中的临床潜力

2025-11-180
OAAI
Supramarginal resection of glioblastoma: An interim analysis of a multicenter randomized controlled trial

胶质母细胞瘤的颞上回后部切除术:一项多中心随机对照试验的期中分析

2025-11-010
OAAI
[18F]Fluoroethyltyrosine and [11C]methionine PET for prognostic stratification of newly diagnosedIDH-mutant gliomas - a retrospective, bicentric cohort study

[18F]氟乙酪氨酸和[11C]蛋氨酸PET在 newly diagnosed IDH-mutant gliomas 的预后分层中的价值——一项回顾性、双中心队列研究

2025-11-010
OAAI
Artificial-intelligence-based morphometric profiling reveals distinctive nuclear characteristics of IDH-mutant vs. IDH-wildtype tumors and non-tumorous tissue at single-cell resolution in label-free Raman imaging

基于人工智能的形态测量分析揭示了IDH突变型与IDH野生型肿瘤以及非肿瘤组织在标签自由拉曼成像中单细胞分辨率的独特核特征

2025-11-010
PRE
FACTORS IMPACTING THE QUALITY OF PATIENT-DERIVED CELLS (PDCS) FOR DRUG SCREENING IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA

影响新诊断胶质母细胞瘤患者药物筛选中患者源性细胞(PDCs)质量的因素

2025-10-010
OAAI
AI-ENHANCED STIMULATED RAMAN HISTOLOGY FOR NEAR REAL-TIME PRIMARY CNS LYMPHOMA IDENTIFICATION AND DIFFERENTIATION FROM OTHER CNS LESIONS

AI增强的受激拉曼组织学技术用于近实时原发性中枢神经系统淋巴瘤识别及与其他中枢神经系统病灶的鉴别

2025-10-010
OAAI
CLINICAL UTILITY OF [18F]FET PET IN PATIENTS WITH CIRCUMSCRIBED ASTROCYTIC GLIOMA

[18F]FET PET在局限性星形细胞胶质瘤患者中的临床应用价值

2025-10-010
OA
AI-BASED NUCLEAR MORPHOMETRY REVEALS DISTINCT MORPHOLOGICAL PATTERNS BETWEEN IDH-MUTANT, IDH-WILDTYPE, AND NON-TUMOROUS CELLS IN STIMULATED RAMAN HISTOLOGY

基于人工智能的核形态测量揭示了刺激拉曼组织学中IDH突变型、IDH野生型和非肿瘤细胞之间的不同形态模式

2025-10-010
OA
A PERSONALIZED TARGETED GLIOBLASTOMA THERAPIES BY EX VIVO DRUG SCREENING: ADVANCED BRAIN TUMOR THERAPY CLINICAL TRIAL (ATTRACT)

通过体外药物筛选实现的个性化靶向胶质母细胞瘤疗法:高级脑肿瘤疗法临床试验(ATTRACT)

2025-10-010
OAAI
Ethical considerations in randomization for neurosurgical oncology trials: A scoping review

神经外科肿瘤临床试验中随机化伦理考量的范围综述

2025-09-010
PRE
Prognostic stratification of newly diagnosed IDH-mutant gliomas by [18F]fluoroethyltyrosine and [11C]methionine PET: A retrospective, bicentric cohort study

Mair, M.J.; Werner, J.-M.; Weller, J.; Barci, E.; Katzendobler, S.; Isakaj, J.; Berchtold, L.; Aras, T.; Stürzl, R.; Hennenberg, J.; 等. 新诊断IDH突变型胶质瘤的预后分层:基于[18F]氟乙酪氨酸和[11C]蛋氨酸PET的回顾性、双中心队列研究。Neuro-Oncology 2025, noaf196. [Google Scholar] [CrossRef]

2025-09-016
PRE